ArticleCancer medicine2026
Multicenter Real-World Evaluation of Neoadjuvant Carboplatin in Triple-Negative Breast Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of carboplatin in neoadjuvant chemotherapy for triple-negative breast cancer (TNBC) remains controversial, particularly in settings where access to immunotherapy is limited. This study evaluated the real-world impact of adding carboplatin to neoadjuvant chemotherapy on pathological complete response (pCR) and survival outcomes in patients with TNBC.
methodsThis retrospective multicenter study included patients with nonmetastatic TNBC treated with neoadjuvant anthracycline- and taxane-based chemotherapy between 2018 and 2023 at three oncology centers in Turkey. Patients were grouped according to receipt of platinum-containing therapy. Survival outcomes were estimated using the Kaplan-Meier method and compared with the log-rank test. Cox regression analyses were performed to evaluate factors associated with survival. Propensity score matching was also performed as a supportive analysis.
resultsA total of 142 patients were included, of whom 45 (32.2%) received platinum-containing neoadjuvant chemotherapy. Overall, 80 patients (56.3%) achieved pCR. The pCR rate was significantly higher in the platinum group than in the non-platinum group (68.9% vs. 50.5%, p = 0.031). After a median follow-up of 57 months, 24 deaths and 33 DFS events were observed. Median OS and DFS were not reached. The 60-month OS rate was 96.0% in the platinum group and 73.9% in the non-platinum group (log-rank p = 0.027), whereas the 60-month DFS rates were 86.1% and 67.6%, respectively (log-rank p = 0.139). Patients who achieved pCR had significantly better OS and DFS than those with residual disease. In the propensity score-matched cohort, non-platinum treatment remained associated with inferior OS and DFS.
conclusionsIn this multicenter real-world cohort, carboplatin was associated with a higher pCR rate and numerically favorable survival outcomes. These findings may be clinically relevant where immunotherapy is not readily accessible but should be considered hypothesis-generating and require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.